Jounce Therapeutics in the spotlight (part III)

Q2 business update and future outlook

Jounce Therapeutics (JNCE) announced 2Q results last week and the company is progressing well on their Phase 1 JTX-8064 (LILRB2 / ILT4) in solid tumors.

Jounce completed enrollment of the monotherapy dose escalation, which was initiated back in January 2021. This part of the Phase 1 included seven doses ranging from 50 mg to 1200 mg. The fast enrollment …